Investment and Company Research
Opportunity Research
MICROCAP HOT TOPICS
 

July 2, 2013

Plandai’s Natural Performance Enhancement for Athletes

Professional and amateur athletes alike are constantly seeking an advantage to fight muscle fatigue and improve physical performance.  There have been countless scandals in professional sports related to illegal or banned performance enhancing drugs. As a result, finding an approved, safe, yet effective alternative is paramount.  This has spurred a growth in sports drinks and other ‘nutraceutical’ products as the athletic-minded consumer looks for an advantage via better performance.  For example, in 2012, Global Industry Analysts (GIA) released a comprehensive report that forecast the consumption of sports and nutrition foods and drinks to be a $55 billion market in the U.S. alone by 2018. 

Plandaí Biotechnology Inc.’s (OTCQB – PLPL - $0.50 – Spec Buy) Phytofare™ Citrus Limonoid Glycoside Complex is a unique product that is primed to serve the unmet needs of these athletes. This offering utilizes the entire fruit including juice, pith, peel, and pulp from where all of the soluble phytonutrients are recovered.  Plandaí­ has spent over a decade developing this botanical extract and has developed a product that delivers the related nutrients more effectively from an absorption perspective than any other comparable product. 

In fact, the innovative product contains all of vitamins A & C, bioflavonoids, (especially Hesperidin and Rutin, limonoids (especially limonin and nomilin), and numerous minerals, including potassium and pectin.  There are three ways this will benefit athletes. First, vitamin C is crucial to aid in immune system strength for extreme athletes like marathon runners.  Second, the minerals and vitamins have been proven to improve and maintain capillary integrity, which enables maximum blood flow and oxidation while training.  Third, there is extensive research showing that citrus bioflavonoids have tremendous anti-inflammatory properties, improving post-injury recovery time. Finally, these components of the Phytofare™ Citrus Limonoid Glycoside Complex formula have demonstrated an ability to strengthen connective tissue, i.e. ligaments and tendons. Previous third-party testing has shown that athletes taking a high-dosage citrus limonoid complex have experienced faster post-work out recovery and the virtual elimination of muscle pulls.

The Company plans to conduct future studies and trials for this product and, once it receives approval and is introduced to the consumer, it will be marketed to include all of the major benefits including enhanced athletic performance.  Clearly, Plandaí’s next generation delivery system and high absorption advantages will give the Phytofare™ Citrus Limonoid Glycoside Complex a superior edge over competitors and presents substantial revenue opportunities in a huge vertical market.

For more information, refer to our previous PLPL Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com

Senior Analyst: Robert Goldman
Rob Goldman has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.

Analyst Certification
I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. 

Disclaimer
This Opportunity Research Hot Topics article was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports. It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. While stocks in the Opportunity format may have a higher risk profile, they typically offer greater upside as well. Since April 2012, Goldman Small Cap Research has been compensated $500 per article by a third party.  All information contained in this report was provided by the Company or derived from GSCR due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.

This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.